we develop immunologic therapeutics and diagnostics designed to make the world a healthier place
Company profile
Ticker
REVB
Exchange
Website
CEO
Andreas Typaldos
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Petra Acquisition Inc.
SEC CIK
Corporate docs
IRS number
843898466
REVB stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
18 Jun 24
8-K
Submission of Matters to a Vote of Security Holders
16 May 24
8-K
Results of Operations and Financial Condition
10 May 24
10-Q
2024 Q1
Quarterly report
10 May 24
DEF 14A
Definitive proxy
15 Apr 24
PRE 14A
Preliminary proxy
5 Apr 24
8-K
Results of Operations and Financial Condition
22 Mar 24
10-K
2023 FY
Annual report
22 Mar 24
8-K
Regulation FD Disclosure
11 Mar 24
8-K
Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering
8 Feb 24
Latest ownership filings
SC 13G/A
Lind Global Fund II LP
13 Feb 24
SC 13G
SABBY MANAGEMENT, LLC
3 Jan 24
4
GEORGE F TIDMARSH
12 Dec 23
4
GEORGE F TIDMARSH
18 Oct 23
4
GEORGE F TIDMARSH
17 Oct 23
3
Lakhmir S Chawla
2 Oct 23
4
GEORGE F TIDMARSH
2 Oct 23
144
Notice of proposed sale of securities
28 Sep 23
4
GEORGE F TIDMARSH
18 Sep 23
4
GEORGE F TIDMARSH
19 Apr 23
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 14.55 mm | 14.55 mm | 14.55 mm | 14.55 mm | 14.55 mm | 14.55 mm |
Cash burn (monthly) | (no burn) | 262.59 k | 634.05 k | 744.91 k | 945.99 k | 712.43 k |
Cash used (since last report) | n/a | 721.16 k | 1.74 mm | 2.05 mm | 2.60 mm | 1.96 mm |
Cash remaining | n/a | 13.83 mm | 12.81 mm | 12.51 mm | 11.95 mm | 12.60 mm |
Runway (months of cash) | n/a | 52.7 | 20.2 | 16.8 | 12.6 | 17.7 |
Institutional ownership, Q4 2023
13F holders | Current |
---|---|
Total holders | 4 |
Opened positions | 0 |
Closed positions | 22 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 1.04 mm |
Total shares | 3.05 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
AXA IM Prime Impact Master Fund I SCA SICAV-RAIF | 1.96 mm | $0.00 |
Linden Capital | 715.75 k | $0.00 |
Lind Global Fund II | 186.50 k | $533.00 k |
Intracoastal Capital | 184.98 k | $511.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Dec 23 | George F Tidmarsh | Common Stock | Sell | Dispose S | No | No | 0.5199 | 27,771 | 14.44 k | 0 |
16 Oct 23 | George F Tidmarsh | Common Stock | Sell | Dispose S | Yes | No | 0.661 | 10,957 | 7.24 k | 42,096 |
16 Oct 23 | George F Tidmarsh | Common Stock | Sell | Dispose S | No | No | 0.6501 | 1,845 | 1.20 k | 27,771 |
28 Sep 23 | George F Tidmarsh | Common Stock | Sell | Dispose S | Yes | No | 0.69 | 1,429 | 986.01 | 42,096 |